Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index

Marco Colleoni, Sigui Li, Richard D. Gelber, Karen N. Price, Alan S. Coates, Monica Castiglione-Gertsch, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). Obese patients were significantly more likely to receive a lower chemotherapy dose (

Original languageEnglish
Pages (from-to)1108-1110
Number of pages3
JournalLancet
Volume366
Issue number9491
DOIs
Publication statusPublished - Sep 24 2005

Fingerprint

Estrogen Receptors
Body Mass Index
Drug Therapy
Methotrexate
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Colleoni, M., Li, S., Gelber, R. D., Price, K. N., Coates, A. S., Castiglione-Gertsch, M., & Goldhirsch, A. (2005). Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet, 366(9491), 1108-1110. https://doi.org/10.1016/S0140-6736(05)67110-3

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. / Colleoni, Marco; Li, Sigui; Gelber, Richard D.; Price, Karen N.; Coates, Alan S.; Castiglione-Gertsch, Monica; Goldhirsch, Aron.

In: Lancet, Vol. 366, No. 9491, 24.09.2005, p. 1108-1110.

Research output: Contribution to journalArticle

Colleoni, M, Li, S, Gelber, RD, Price, KN, Coates, AS, Castiglione-Gertsch, M & Goldhirsch, A 2005, 'Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index', Lancet, vol. 366, no. 9491, pp. 1108-1110. https://doi.org/10.1016/S0140-6736(05)67110-3
Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005 Sep 24;366(9491):1108-1110. https://doi.org/10.1016/S0140-6736(05)67110-3
Colleoni, Marco ; Li, Sigui ; Gelber, Richard D. ; Price, Karen N. ; Coates, Alan S. ; Castiglione-Gertsch, Monica ; Goldhirsch, Aron. / Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. In: Lancet. 2005 ; Vol. 366, No. 9491. pp. 1108-1110.
@article{09c17bb965634dab930f5df4a76ab329,
title = "Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index",
abstract = "Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). Obese patients were significantly more likely to receive a lower chemotherapy dose (",
author = "Marco Colleoni and Sigui Li and Gelber, {Richard D.} and Price, {Karen N.} and Coates, {Alan S.} and Monica Castiglione-Gertsch and Aron Goldhirsch",
year = "2005",
month = "9",
day = "24",
doi = "10.1016/S0140-6736(05)67110-3",
language = "English",
volume = "366",
pages = "1108--1110",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9491",

}

TY - JOUR

T1 - Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index

AU - Colleoni, Marco

AU - Li, Sigui

AU - Gelber, Richard D.

AU - Price, Karen N.

AU - Coates, Alan S.

AU - Castiglione-Gertsch, Monica

AU - Goldhirsch, Aron

PY - 2005/9/24

Y1 - 2005/9/24

N2 - Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). Obese patients were significantly more likely to receive a lower chemotherapy dose (

AB - Clinicians often reduce chemotherapy doses when treating obese patients because of concerns about overdosing. We assessed dose-response according to body-mass index (BMI) and oestrogen receptor (ER) expression of the primary tumour in premenopausal patients with node-positive breast cancer treated with classical CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). Obese patients were significantly more likely to receive a lower chemotherapy dose (

UR - http://www.scopus.com/inward/record.url?scp=25144466036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144466036&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(05)67110-3

DO - 10.1016/S0140-6736(05)67110-3

M3 - Article

C2 - 16182899

AN - SCOPUS:25144466036

VL - 366

SP - 1108

EP - 1110

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9491

ER -